Webinar: Power of Modern Trial Infrastructure for Accelerated Drug Development

Webinar: Power of Modern Trial Infrastructure for Accelerated Drug Development

Webinar: AI and Cloud – Power of Modern Trial Infrastructure for Accelerated Drug Development

Speed, quality, and cost of drug development depend on the robust clinical trial design, targeted patient selection and optimal efficacy assessments. Imaging is increasingly used in clinical trials to improve success rate and reveal early evidence of treatment impact.

IAG, Image Analysis Group is a leading medical imaging expert company driving the use of quantitative imaging as an early evidence for drug development. We improve speed and reproducibility of radiological reviews with Computer-Aided workflows and bring smart often AI driven methodologies to extract the full spectrum of information from medical images. Thus, giving biotech or pharma companies early powerful efficacy data in clinical trials.

In this webinar, we will present our proprietary cloud-based platform DYNAMIKA and show how it can increase efficiencies of traditional radiological reviews while integrating the best of advanced quantitative image analysis in clinical trials.

We will show how the flow of an imaging part of a clinical trial improves when operational teams can take advantage of automated data de-identification, built-in audit trail and notification system, automated quality control, and seamless workflows for all trial stakeholders.

Our therapeutic experts will show case studies of early drug evidence, trial enrichment and advanced treatment efficacy assessments from phase I-IV trials in oncology, neurology, and rheumatology.

This webinar will be interesting to those who are responsible for clinical trials operations, design of clinical trial protocols, imaging biomarker selection, patient recruitment and overall success of clinical programs.

Date and Time:

Friday, May 21 2021, 12 PM ET / 5 PM BST

Register on Xtalks

For questions or a replay, email imaging.experts@ia-grp.com

What you will learn:

  • De-risking clinical trials and accelerating drug development through efficient central imaging data management and centralized review.
  • Powering your trial with DYNAMIKA in a global multi-centre trial setting and delivering complex imaging trials.
  • AI-powered controls over your image data quality and radiological reviews.
  • Insight into the advanced data analytics / advanced quantitative approaches and their impact on the efficacy data.

Speakers:

Dr. Olga Kubassova, CEO of IAG and life science innovator, mathematician with expertise in actively managing innovation in life science companies, asset positioning, and strategy. Extensive expertise and domain knowledge in identifying innovative approaches to clinical research, disruptive technology platforms and novel therapeutics. Olga is an active researcher, with over 80 publications, books and book chapters. She is a scientific adviser to the UK government and EU funding bodies. Her ambition is to bring truly disruptive technologies, artificial intelligence and best of machine learning to clinical practice and research, while expanding IAG’s footprint and partnerships.

Prof. Jamshid Dehmeshki, CTO of IAG, is a software engineer with passion for medical imaging and 20+ years of mixed academic and commercial background. He is supporting IAG’s bio-pharma clients in the design and delivery of complex imaging trials that require the best in breed technology solutions. Jamshid’s experience is in enterprise development environments, medical device quality control, algorithm development and patenting novel approaches to medical image analysis. He is widely published academic and recognized speaker in the field of medical image analysis, data mining, algorithm development, medical image and video processing, mathematical, stochastic and forecasting modelling and numerical analysis. He has published more than 170 scientific research papers, five book chapters, and holds thirteen patents.

Prof. Mikael Boesen, MD, PhD, Head of Musculoskeletal Research at IAG, professor of radiology with focus on musculoskeletal imaging and head of the musculoskeletal imaging and research at Copenhagen University and Bispebjerg and Frederiksberg Hospital in the Capital region of Denmark. He has 20 years hands-on international experience in clinical research in inflammatory and degenerative joint diseases and serves as a global PI on trials. He is an author of 130+ articles, 6 book chapters and 160 abstracts and he has served as supervisor of more than 20 PhD students and postdocs. He brings together cross-therapeutic area expertise into musculoskeletal imaging from previous work in immuno-oncology and cardiac imaging and he currently spearheads implementation of artificial intelligence into radiological image analysis in Denmark, EU the US all of which he uses to helps drug developers and biotech companies to think outside the box when it comes to designing clinical trials and selecting appropriate imaging strategy within many therapeutic areas.

Prof. Sotirios Bisdas, MD, PhD Head of Neuro-Oncology and Neurology at IAG, neuroradiologist, Senior Lecturer at the Institute of Neurology, UCL, London, UK and professor in radiology at the University of Tübingen, Germany. He is an expert and a distinguished PI in many international clinical studies, which rely on the use of cutting-edge methodologies and advanced imaging in assessing efficacy of novel treatments for brain tumours and other neurological conditions. He co-authored 130 peer-reviewed publications, 7 book chapters related to advanced MRI in neurological and oncological diseases. He is actively involved in designing and publishing guidelines for the use of perfusion imaging in Oncology.

News
Events

Black & White Answers to Tough Questions in RA Drug Development

Black & White Answers to Tough Questions in RA Drug Development

Drug Development in Rheumatoid Arthritis: Black and White Answers to Tough Questions

We picked 3 hot topics and invited 3 outstanding speakers to join a live webinar focused on the drug development in Rheumatoid Arthritis (RA):

–    Unmet needs in RA drug development: do we still need new therapies?
–    Trial design: is clinical score enough?
–    Earlier decisions in RA drug development: how imaging and technology can support your clinical programs?

If you are interested in a replay, please reach out to imaging.experts@ia-grp.com

About the Webinar

While the rheumatoid arthritis drug pipeline is robust with over 240 molecules under study, many will drop off through natural attrition. It has been shown that only 40% of patients are ACR70 responders, which indicates a need for more effective treatment options.

The drug development process is complex, with greater focus being put on personalization of therapeutic strategies, both in the choice of molecules and their place in a patient treatment pathway.

This webinar will be a live discussion on several hot topics.

The moderator and the speakers will start with discussing the need for new therapies and what new therapies mean for the market.

The second topic will be focused on trial design, remission as an outcome, patient inclusion, trial enrichment and patient phenotyping.

The third topic is the use of imaging biomarkers and technology to achieve earlier decisions on treatment efficacy and practical aspects of RA clinical trials.

Dr. Lee Simon, MD
is a rheumatologist, physician and research scientist with extensive drug development experience. He served as a director of FDA division for of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products and currently advises many biotech and pharma companies on designing impactful clinical programs. Dr. Simon is Principal Consultant and member of IAG’s Scientific Advisory Board.

Prof. Mikael Boesen, MD, PhD
is a professor of musculoskeletal imaging and hands-on radiologist with 20 years of international experience in clinical research in inflammatory and degenerative joint diseases. Dr. Boesen is a global PI, speaker, and author of 130+ articles and book chapters. He brings together cross-therapeutic area expertise and helps drug developers to think outside the box when it comes to designing clinical trials and selection imaging strategy. Prof. Boesen is IAG’s Lead for Musculoskeletal Clinical Research.

Prof. Philip Conaghan, MB, BS, Phd, FRACP, FRCP

is an academic rheumatologist and Director of the arthritis research Institute at the University of Leeds, UK. He has major research interests in understanding pathogenesis and improving the therapies for common arthritides, especially osteoarthritis, rheumatoid and psoriatic arthritis, with a focus on outcome measurement, modern imaging modalities, and optimising patient phenotypes for clinical trials and practice.

Moderator: Dr. Olga Kubassova
is CEO of IAG, Image Analysis Group, mathematician and computer scientist with 10+ years expertise in actively managing innovation in life science companies. Scientific interests are in quantitative imaging and development of novel efficacy methodologies, with AI, Machine Learning for fast objective early decisions in clinical trials.

About IAG, Image Analysis Group:
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com

News
Events

Webinar: The Role of Central Imaging in Successful Oncology Clinical Trials

Webinar: The Role of Central Imaging in Successful Oncology Clinical Trials

The Role of Central Imaging in Successful Oncology Clinical Trials

Today’s oncology R&D programs require precision in early go / no go decisions and clarity on the treatment impact.

Despite the FDA’s guidance on the imaging endpoint process, research shows that variability of site reads vs central reads is typically between 5-30%.

At IAG, we developed and implemented in over 400 trials a modern trial infrastructure for centralized data collection and central imaging review.

In this live webinar, IAG’s imaging experts will share their experience in delivering central review in oncology clinical trials, with enterprise level platform DYNAMIKA that provides efficiencies, compliance, and security in data management. We will show how such a set-up allows to reduce variability in the reads, both radiology assessments and quantitative image review criteria.

We will discuss added efficiencies and cost savings enabled by DYNAMIKA. Our experts will cover advantages of quantitative imaging alongside standard radiographic response criteria, such as RECIST 1.1, iRECIST, RANO, and Lugano.

If you are interested in a replay, please reach out to imaging.experts@ia-grp.com

Key Discussion Points:

  • Importance of centralized image interpretation
  • Quantitative image analysis and radiological assessments:  the need of centralized imaging interpretations
  • Choosing the right imaging strategy and platform for your clinical trial.

Followed by a Q&A.

Speakers:

Dr Diana Dupont-Roettger, IAG’s Chief Scientific Alliance Officer

Medical computer scientist by background, with strong experience in world-class academic research, biotechnology industry, pharma and investment. 10+ years of experience in the strategic use of medical imaging in the assessment of drug efficacy, trial conceptualizing, trial design and de-risking. Actively working with biotech companies to bridge the gap between academic research and their strategy for commercialization.

Sebastien Jacques, IAG’s Senior Project Manager

12+ years of experience in managing central imaging review for oncology clinical trials. Highly skilled in all aspect of Project Management, Software Engineering and Information Technology. Effective management of multiple oncology imaging projects and the project teams from study start-up to database lock with excellent operational planning and oversight, risks mitigation, resource, time and budget planning.

David Chia, CCO and Head of Bio-partnering

Senior executive with over 16 years of experience in strategic clinical development and operational analysis for biotechnology, pharma and life sciences companies. Expertise in creating and maintaining successful strategic partnerships between service providers and sponsors. Highly experienced in all aspects of clinical development including central imaging solutions.

About IAG:
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com

News
Events

Webinar: Advanced Imaging in Brain Cancer Therapy Development

Webinar: Advanced Imaging in Brain Cancer Therapy Development

Join IAG and WPD Pharmaceuticals’ Experts to Discuss the Potential of Advanced Imaging to Show Early Treatment Effects of Berubicin in Brain Cancer

Join Mariusz Olejniczak, CEO of WDP Pharmaceuticals, and Diana Dupont-Roettger, Chief Scientific Alliance Officer of IAG, during a live webinar to discuss how advanced imaging can show early treatment effects in brain cancer.

Bringing a novel glioblastoma multiforme (‘GBM’) therapy to the market requires a robust clinical trial that will assess the effectiveness of the potential treatment. The design and delivery of such trials is a challenge.

If you are interested in a replay, please reach out to imaging.experts@ia-grp.com

About the Webinar:

WPD Pharmaceuticals (‘WPD’) is a biotechnology research and development company focused on developing drug candidates involved in targeted therapy for brain cancers. Its lead drug candidate, Berubicin, is proposed for the treatment of GBM, an aggressive and incurable form of brain cancer. www.wpdpharmaceuticals.com

IAG, Image Analysis Group (‘IAG’) is a leading medical imaging company and will work closely with WPD to provide critical imaging services, its proprietary platform DYNAMIKA and imaging data analysis to assess the effects of Berubicin in a phase II clinical trial in patients with GBM.

Advanced cancer therapies, such as WPD’s Berubicin treatment, often lead to pseudo-progression, a local tissue reaction resulting from immune cell infiltration, causing inflammation, tumor necrosis and oedema which are often misinterpreted as tumor growth on traditional MRIs.
Pseudo-progression is difficult to distinguish from disease progression using routine clinical radiographic assessments. This is where non-invasive methods are needed to enhance the understanding of complex neuro-pathologies.
Novel imaging strategies and artificial intelligence (‘AI’) driven imaging biomarkers can advance neuro-oncology clinical trials by providing deep analysis of disease progression and treatment response. They are most efficiently integrated in clinical trials when implemented using a cloud-platform, such as IAG’s DYNAMIKA, that combines central review of standard radiographic endpoints, such as Response Assessment in Neuro-Oncology (‘RANO’), as well as advanced imaging endpoints in a cost and time efficient fashion.
Register for this joint webinar from WPD and IAG to learn more about Berubicin and how the development of novel brain cancer therapies ca be advanced with the use of AI and efficient imaging data management.

Key discussion points:

  • Increasing chances of success in brain chancer drug development with the use of modern trial infrastructure and advanced imaging.
  • Selection of imaging biomarkers that go beyond conventional radiographic assessments and can identify pseudoprogression and treatment-related changes early.
  • Enabling advanced imaging strategies in global multi-center clinical trials.
  • De-risking clinical trials and accelerating drug development through efficient central imaging data management and centralized review.

About Mariusz Olejniczak:

Graduate of Biotechnology at the University of Life Sciences in Poznań. Experienced professional in medicinal products, medical devices, supplements and plant protection products R&D at every stage – from planning and scientific advice through supervision to the closure and finalization of the project. A founder of several start-ups in the e-health industry and a member of the board and supervisory board of several R&D companies. Author of the publication „Change of the product development model as an opportunity for the Polish pharmaceutical industry” (in Polish). Member of the editorial committee of the book „Clinical Trials” (in Polish). Lecturer in postgraduate study programs.

About Dr. Diana Dupont-Roettger:

Medical Computer Scientist by background with strong experience in novel imaging technologies, AI and imaging markers and their role in clinical trials. She advises biopharmaceutical companies on the strategic use of advanced imaging to evaluate mechanism of action, enable precision medicine and accelerate drug development in immuno-oncology and neuro-oncology indications.

News
Events

12th March Webinar: Speak to the IT Girls!

12th March Webinar: Speak to the IT Girls!

Meet IAG’s female technology leaders in a live discussion: sharing our story, career journey and aspirations.

The 8th March is International Women’s Day. This is the day for recognition and empowerment of our female leaders.

In 2021, this day marks nearly 12 months of the world’s covid troubles and importance of science.

2021 just calls to make this day extra special and talk about women in technology, science, and clinical research!

On this special day, we send our warmest wishes and want to invite you to join a live discussion with 4 inspirational female leaders of IAG. They will share their journey, career path and aspirations.

Dr. Olga Kubassova, IAG’s CEO and Founding Scientist, Dr. Diana Dupont-Roettger, IAG’s Chief Scientific Alliance Officer, Julia O’Lynn, IAG’s Imaging Specialist and Technologist, and Romiesa Hagoug, IAG’s Sn Project Manager.

If you are interested in receiving a replay link, please email imaging.experts@ia-grp.com

Key Discussion Points:

  • My personal journey and joining clinical research industry,
  • What does technology, science and entrepreneurship mean to me,
  • My challenges and wins in day-to-day professional life,
  • My aspirations, ambitions, and advice I want to give to the future leaders.

Followed by a discussion and Q&A.

Who Should Attend:

A person of any age, any gender, any occupation who feels that they can draw insights from our life stories and our journey and make these useful to your family, colleagues or friends.

If you cannot attend, just register and you will receive a replay link!

About IAG:
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com

News
Events

Webinar: Psoriatic Arthritis – Clinical Development Insights

Webinar: Psoriatic Arthritis – Clinical Development Insights

IAG’s Imaging Expert Team Discuss Psoriatic Arthritis – Clinical Development Insights

Join Dr. Olga Kubassova, Prof. Mikael Boesen, and Prof. Philip Mease during a live webinar to discuss how medical imaging can support targeted patient selection and more precise, objective assessment of the treatment impact.

If you are interested in receiving a replay link, please email imaging.experts@ia-grp.com

About the Webinar:

One of the challenges in treatment of patients with Psoriatic Arthritis  (PsA) is the disease’s variable presentation. PsA may present in several clinical domains, including synovitis, dactylitis, skin disease, nail disease, spine disease (spondylitis) and each of these domains has subtly different immunologic pathophysiology drivers. Thus, drug developers may find that their new therapies do very well in individual patients or within some of the domains. Medical Imaging, quantitative biomarkers coupled with efficiencies of modern scanners can support targeted patient selection and more precise objective assessment of the treatment impact.

Key discussion points:

  • How can we assess a new treatment efficacy through a clinical trial designed to give us a new comprehensive understanding of the treatment’s impact?
  • Are there biomarkers and imaging techniques which can help differentiate patients early?
  • State-of-the-art and emerging imaging techniques in trials of psoriatic arthritis
  • Imaging biomarkers – in patient selection and efficacy assessment of new treatments targeting PsA

About Dr. Olga Kubassova:
Mathematician and computer scientist with 10+ years expertise in actively managing innovation in life science companies. Scientific interests are in quantitative imaging, development of novel efficacy methodologies, AI, Machine Learning in clinical trials.

About Prof. Mikael Boesen:
Mikael Boesen is currently employed as professor of radiology with focus on musculoskeletal imaging, and head of the musculoskeletal imaging and research at Copenhagen University and Bispebjerg and Frederiksberg Hospital in the Capital region of Denmark. He has 20 years hands-on international experience in clinical research in inflammatory and degenerative joint diseases and serves as a global PI and speaker as well as author of 120+ articles, 6 book chapters and 160 abstracts and he has served as supervisor of more than 20 PhD students and postdocs. He also brings together cross-therapeutic area expertise into MSK imaging from previous work in immuno-oncology and cardiac imaging and he currently spearheads implementation of artificial intelligence into radiological image analysis in Denmark, EU the US all of which he uses to helps drug developers and biotech companies to think outside the box when it comes to designing clinical trials and selecting appropriate imaging strategy within many therapeutic areas

About Prof. Philip Mease:
Dr. Mease is an international key opinion leader, researcher, educator and clinician who cares for patients at Seattle Rheumatology Associates, directs the rheumatology research division at Swedish Medical Center/Providence St. Joseph Health and is Clinical Professor of Medicine at the University of Washington in Seattle. His research interests include psoriatic arthritis and spondyloarthritis, rheumatoid arthritis, osteoarthritis, fibromyalgia and osteoporosis. He is a reviewer for multiple journals including New England Journal of Medicine, Lancet, Arthritis & Rheumatology, Arthritis Care & Research, Annals of the Rheumatic Diseases, The Journal of Rheumatology, and Seminars in Arthritis and Rheumatism. He is a past president and founding organizer of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), active contributor to Outcome Measures in Rheumatology Clinical Trials (OMERACT) research group and serves in an educational and advisory role for the FDA.

About IAG:
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com

News
Events

Webinar: Osteoarthritis & Cartilage – Intricacies of Imaging in Clinical Trials

Webinar: Osteoarthritis & Cartilage – Intricacies of Imaging in Clinical Trials

 Osteoarthritis & Cartilage – Intricacies of Imaging in Clinical Trials

Join Dr. Olga Kubassova, CEO and Prof. Mikael Boesen, Head of Musculoskeletal Imaging Research during a live webinar to discuss optimal use of imaging to empower clinical development of novel therapeutics in osteoarthritis and cartilage repair.

If you are interested in receiving a replay link, please email imaging.experts@ia-grp.com

About the Webinar:

A rising need for effective treatment that can both reduce pain and positively impact cartilage repair makes drug developers innovate in trial designs and use more informative biomarkers, including imaging.

Key discussion points:

  • Patient selection and appropriate use of imaging to account for comorbidities
  • FDA approved imaging endpoints for disease modification claims and use of AI in increasing their sensitivity
  • Novel imaging and scoring for osteoarthritis and cartilage repair clinical trials

About Dr. Olga Kubassova:
Mathematician and computer scientist with 10+ years expertise in actively managing innovation in life science companies. Scientific interests are in quantitative imaging, development of novel efficacy methodologies, AI, Machine Learning in clinical trials.

About Prof. Mikael Boesen:
Prof. of musculoskeletal imaging, hands-on radiologist with 20 years of international experience in clinical research in inflammatory and degenerative joint diseases. Dr. Boesen is a global PI, speakers and author of 80+ articles and book chapters. He brings together cross-therapeutic area expertise and helps drug developers to think outside the box when it comes to designing clinical trials and selection imaging strategy.

About IAG:
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com

News
Events

Webinar: Successful Oncology Clinical Trials

Webinar: Successful Oncology Clinical Trials

IAG’s Imaging Expert Team Discuss Successful Oncology Clinical Trials and the Impact of Novel Technologies

Join Dr. Diana Dupont-Roettger, Chief Scientific Alliance Officer and Sebastien Jacques, Senior Project Manager for Oncology during a live webinar to discuss the role of new technology and imaging that support successful oncology clinical trial delivery.

Replay link is available here

Request password: imaging.experts@ia-grp.com or diana.roettger@ia-grp.com

About the Webinar:

IAG’s imaging experts will share their experience in designing and delivering oncology clinical trials, that use quantitative imaging alongside standard radiographic response criteria, such as RECIST 1.1, iRECIST, RANO, Lugano.

The individual steps that are crucial for successful imaging data management that complies with latest regulatory requests will be outlined and discussed.

In addition, the team will highlight how the use of DYNAMIKA, IAG’s cloud based trial infrastructure, adds efficiencies and cost savings.

Key discussion points:

  • Quality, Integrity and Security of data in a cloud-based trial infrastructure
  • Speed of the processes and ability to make decisions fast
  • Change between high level trial overview and details
  • Real time availability of data
  • Transparency of stakeholders’ performance
  • Integration of Advanced Imaging

 

 

About Sebastien Jaques, MSc, PMP:

Experienced Project Manager with a 12+ years of history of working in the pharmaceuticals industry. Skilled in Management, Software Engineering and Information Technology, as well operational planning and oversight, planning of risks, resource, time, budget and effectively managing the project and the project team from concept to database lock.

About Dr. Diana Dupont-Roettger:
Diana is a Medical Computer Scientist by background with strong experience in novel imaging technologies and imaging markers as well as their role for biotech and pharma. She is an expert in scientific imaging clinical trial design and advises biotech and pharma on the strategic use of advanced imaging to evaluate mechanism of action, enable precision medicine and accelerate drug development in immuno-oncology and neuro-oncology indications. Diana is actively working with biotech, pharma and investment funds helping to bridge the gap between academic research, business objectives and finances.

About IAG:
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com

News
Events

In Drug development, Data is everything.

In Drug development, Data is everything.

Streamlining Clinical Trials with IAG’s Proprietary Cloud Platofrm, DYNAMIKA

Data is your evidence of drug efficacy. It is the ‘must have’ of your clinical development program.

Imaging data is a rich source of information of objective response and early evidence of efficacy.  It reveals different dimensions of your drug’s MoA.

…and you can literally SEE your patients’ response.

The power of imaging-based evidence is hidden under a pile of inefficiencies associated with its collection and the screaming absence of quantitative approaches to explain its value.

Join our team in a live webinar to discuss how to streamline imaging clinical trials and accelerate drug efficacy decisions.

PART 1: MODERN TRIAL INFRASTRUCTURE: STREAMLINING TRIAL OPERATIONS

Date: Thursday, 28 May 2020, 11 am EST / 4 pm GMT

Key Discussion Points:

  • DYNAMIKA in a global multi-centre trial setting
  • AI-powered controls over your data quality
  • Insight into the advanced data analytics

PART 2: DYNAMIKA & QUANTITATIVE IMAGE ANALYSIS LIBRARIES

Date: Fri 29 May 2020, 10 am EST / 3 pm GMT

Key Discussion Points:

  • Advanced quantitative approaches
  • Radiomics, AI and Machine Learning for assessment of treatment response
  • Making efficacy decisions in clinical trials

It is going to be technical but fascinating! The webinars will presented by IAG’s leadership team and project managers and scientists.

At IAG, we developed DYNAMIKA to help bio-pharma innovators turning the page and steping into the new era of efficiencies and objective evidence.

IAG has been driving the use of quantitative imaging as an early evidence for drug development for over a decade.

DYNAMIKA is our platform that brings together smart image analysis methodologies, AI and Machine Learning to ensure speed and cost-effectiveness, while delivering true insights about your mechanism of action and patients’ response, in real-time.

About the Speakers:

Dr. Olga Kubassova, CEO of IAG, Image Analysis Group. She is a mathematician, computer scientist and entrepreneur, playing a significant role in the development and use of medical imaging in clinical research and diagnosis. 

Dr. Jamshid Dehmeshki, CTO of IAG, has over 20 years of experience in medical image analysis particularly in developing computer aided diagnosis systems. He is AI expert who tool products from conception to FDA approval. 

Questions or need help registering, please email <imaging.experts@ia-grp.com> 

 

News
Events

Novel Imaging Approaches for Precision Medicine in Neuro-Oncology

Novel Imaging Approaches for Precision Medicine in Neuro-Oncology

Novel Imaging Approaches for Precision Medicine in Neuro-Oncology

Non-invasive methods are needed to enhance our understanding of complex neuropathologies. Novel imaging strategies can advance neurology and neurooncology clinical trials by providing deep analysis of disease progression and treatment response.

Join our live webinar – Novel Imaging Approaches for Precision Medicine in Neuro-Oncology jointly presented by Prof. Sotirios Bisdas, IAG’s Senior Director, Oncology and Neurological Disease Imaging and Dr. Diana Dupont-Roettger, IAG’s Chief Scientific Alliance Officer.

Key discussions points:

  • Current challenges and unmet needs for neuro-oncology imaging
  • Novel neuro-imaging strategies in clinical trials
  • A novel paradigm in decision-making: Radiological Phenotyping, True Progression vs. Pseudo-Progression

The session will begin with the joint presentation and will then be followed by a live Q&A to give the audience a chance to gain insight into their own development programs.

Date: Thursday, 14 May 2020

Time: 11 am EST / 4 pm GMT

Register here !

About the Webinar:

This webinar is organized by IAG, Image Analysis Group, a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. www.ia-grp.com

Prof. Sotirios Bisdas is a consultant neuroradiologist and MRI Lead in the Department of Neuroradiology at the National Hospital for Neurology in London, Senior Lecturer in Neuroradiology at the Institute of Neurology University College London, and Professor of Radiology at Eberhard Karls University in Tübingen, Germany. He has authored over 130 peer-reviewed publications and serves as member of the editorial board of several leading journals in Radiology and Neuroradiology. He is also reviewer for leading journals in Neuroimaging, member of the Executive Committee of the European Society of Head and Neck Radiology, and member of the Head and Neck committee of the European Society of Neuroradiology.

Dr. Diana Dupont-Roettger is a Medical Computer Scientist by background with strong experience in novel imaging technologies and imaging markers and their role in clinical trials. She advises biopharmaceutical companies on the strategic use of advanced imaging to evaluate mechanism of action, enable precision medicine and accelerate drug development in immuno-oncology and neuro-oncology indications. Diana is actively working with biotech, pharma and investment funds helping to bridge the gap between academic research, business objectives and finances.

Questions or need help registering, please email <imaging.experts@ia-grp.com>

News
Events